Company intelligence / Profile preview

Synartro

Solna, Stockholms län, Sweden

Ownership: Private
Development stage: Other

Overview

Synartro's lead asset, SYN321, is in a Phase 1/2a trial to evaluate safety, tolerability, systemic exposure, and preliminary efficacy in symptomatic knee osteoarthritis. The study aims to demonstrate rapid and sustained pain relief with fewer systemic side effects than standard therapies, leveraging the local conjugation of diclofenac to hyaluronic acid for direct joint injection. As of mid-2025, the first-in-human study is starting or ongoing.

Therapeutic areas: Rheumatology
Modalities: Small moleculePolymer-drug conjugate therapy
Industry: Biotech

Drug pipeline

1 asset

SYN321

Partnerships

Clinical Trial Consultants AB (clinical study execution)

Beyond the preview

Go deeper on Synartro.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synartro.

Explore the full profile